Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Sales of Investments

Cash received from selling or redeeming investments.

Puma Biotechnology, Inc.NASDAQ: PBYI

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments growth accelerates

Q1 FY2026 sales of investments of $27.34M rose 93.9% year over year, ahead of the +33.1% change in trailing-twelve-month sales of investments. Sequentially, it rose 37.2% from the prior quarter. Over 3 fiscal years it compounded at +56.1% a year.

Context

  • Sales of investments amounted to 31.5% of revenue in FY2025, up 7.3 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +93.9% holds above the trailing-twelve-month pace of +33.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$27.34M+37.2% QoQ
Last fiscal yearDec 2025
$72.02M+29.0% YoY
LTMMar 2026
$85.26M+33.1% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+93.9%——
1 year+29.0%——
3-year CAGR+56.1%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
72.02M USD
Year-over-year change
+29.0%
4-year CAGR
+27.6%

Sales of Investments vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +33.1% is the 2nd highest of 9, against a peer median of -12.9%.
  • Sales of investments amounts to 37.5% of revenue for PBYI, versus a peer median of 80.9%.
PBYI Competitors
Sales of Investments for PBYI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TNGXTango Therapeutics, Inc.LTM Sep 2026$254.25M USD-5.8%-2.5%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$225M USD-27.4%+24.5%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$223.03M USD+378.2%——
NUVBNuvation Bio Inc.LTM Jun 2026$139.19M USD-130.9%-7.5%81.9%
MGNXMacroGenics, Inc.LTM Mar 2026$125.44M USD-4.7%-21.0%79.9%
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$106.52M USD-20.1%+1.5%—
PBYIPuma Biotechnology, Inc.LTM Mar 2026$85.26M USD+33.1%+56.1%37.5%
CRDFCardiff Oncology, Inc.LTM Mar 2026$67.84M USD+28.1%-17.5%12922.7%
NBPNovaBridge BiosciencesLTM Sep 2025CN¥531.77K CNY—-73.0%—
VSTMVerastem, Inc.LTM Mar 2026$119K USD-100.4%-93.0%0.2%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$0 CAD———
Peer median (excluding PBYI) —-12.9%-12.5%80.9%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(29.13M)2K21.59M30.28M31.11M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
Deferred Income Tax000(7.08M)3.25M
Stock-Based Compensation32.63M11.83M10.25M8.25M6.94M
Change in Working Capital(1.31M)(44.5M)(17.85M)(3.54M)(10.08M)
Accounts Receivables(5.98M)(7.82M)(8.37M)16.35M(21.28M)
Inventory(3.66M)2.58M(2.55M)(1.64M)3.21M
Accounts Payables(902K)(4.73M)449K(1.38M)(453K)
Other Working Capital9.23M(34.52M)(7.38M)(16.86M)8.45M
Other Non-Cash Items7.15M7M1.51M(519K)(358K)
Operating Cash Flow20.65M(15.83M)27.01M38.92M41.8M
Capital Expenditures0(7M)(12.64M)(56K)(71K)
Acquisitions (Net)00000
Purchases of Investments(38.07M)(4.84M)(23.81M)(76.23M)(108.14M)
Sales of Investments27.19M18.94M17.33M55.85M72.02M
Other Investing Activities00(12.5M)00
Investing Cash Flow(10.88M)7.1M(19.13M)(20.44M)(36.19M)
Debt Repayment(1.5M)00(33.33M)(44.44M)
Common Stock Issued012.5M0150K130K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(30.43M)(277K)0(666K)(888K)
Financing Cash Flow(31.93M)12.22M0(33.85M)(45.2M)
Effect of Forex Changes00000
Net Change in Cash(22.16M)3.5M7.88M(15.37M)(39.58M)
Free Cash Flow20.65M(22.83M)14.37M38.86M41.73M

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.